WO2010074532A2

WO2010074532A2 - Radioactive cell marker

Info

Publication number: WO2010074532A2
Application number: PCT/KR2009/007780
Authority: WO
Inventors: 유정수; 전학림; 나빈챤드라 판댜달판; 이화영; 오지은
Original assignee: 경북대학교 산학협력단
Priority date: 2008-12-24
Filing date: 2009-12-24
Publication date: 2010-07-01
Also published as: WO2010074532A9; WO2010074532A3; KR101130737B1; KR20100075412A

Abstract

The present invention relates to the radioactive marker compound of chemical formula 1 or 2, a composition containing the radioactive marker compound, and a method for preparing the radioactive marker compound. The marker compound of the invention enables cells to be marked with high efficiency and the movements of a marked cell to be monitored over a long period.

Description

Radioactive cell markers

The present invention relates to a radioactive cell marker capable of tracking the movement of a cell for a long time, and more particularly, a radiolabeled compound capable of tracking the movement of a cell for a long time, a radiolabeled composition comprising the radiolabeled compound And it relates to a manufacturing method thereof.

Positron emission tomography (PET) has the potential to image the location and distribution of cells injected into living organisms. In particular, labeling and imaging cells injected into the body may be utilized in various fields such as tissue engineering for treatment or regeneration through the delivery of biofactors.

Limited methods for labeling cells using various PET nuclides have been developed. Cells labeled with F-18 and Cu-64 have been reported to be able to track cell movement for hours to 1-2 days. PTSM ([64Cu] pyruvaldehyde-bis- (n ⁴ -methyl-thiosemicarbazone) was able to label cells for longer periods. F-18, a method for labeling cells, is typically [ ¹⁸ F] FDG (2- [ Cell trapping with ¹⁸ F] fluoro-2-deoxy-D-glucose metabolites or acylation of cells using [ ¹⁸ F] FSB (N-succimidyl-4- [ ¹⁸ F] fluorobenzoate) There is a way.

However, both methods have disadvantages. Incubation of labeled cells with [ ⁶⁴ Cu] PTSM or [ ¹⁸ F] FDG allows the separation of labeled cells, but after several hours it is difficult to interpret the imaging data from the cells to measure radioactivity in the body. Because the radiolabeled substance is covalently linked to the cell, the labeled cell and [ ¹⁸ F] FSB are believed to be more permanently bound, but prior results indicate that the alkylated moiety is released in metabolism and the marker is released from the cell. It is considered to be out. In addition, the synthesis of the [ ¹⁸ F] FSB has a disadvantage that the synthesis is difficult. In order to overcome these shortcomings, [ ¹⁸ F] HFB (Hexadecylfluorobenzoate) having high labeling efficiency and easy synthesis of F-18 was synthesized. However, this compound is only suitable as a short-term trafficking agent since the half-life of F-18 is 110 minutes.

Cell markers that can efficiently label cells with high yield and enable long-term follow-up of cell movement in vivo using nuclear medical imaging equipment such as PET (Positron Emission Tomography) or Single Photon Emission Computed Tomography (SPECT) Development is required.

The present invention seeks to develop an improved labeling compound for long-term follow-up using radiation iodine such as ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I.

Specifically, the present invention relates to a radiolabeled compound of Formula 1 or Formula 2.

Formula 1

Wherein X is a radioisotope of iodine, 5 ≦ i + j ≦ 30, and N is 1 to 10, which may have 1 to 10 double bonds (-CH = CH-) in this portion. The double bond (-CH = CH-) may be continuously connected or in some cases discontinuously. That is, when a double bond is continuous, for example, (-CH = CH-CH = CH-CH = CH -...), and when the double bond is discontinuously bonded, (-CH = CH-CH ₂ -CH = CH-CH = CH-), (-CH = CH-CH ₂ -CH ₂ -CH = CH-CH = CH-), (-CH = CH-CH ₂ -CH = CH-CH _2- It means that -CH ₂ -may be bonded between the double bond, such as CH = CH-). In particular, the radioisotope of iodine is selected from the radioisotope group of iodine consisting of ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I, more preferably ¹²³ I, ¹²⁴ I, ¹²⁵ I , ¹³¹ I.

Formula 2

Wherein X is the radioisotope of iodine and 5 ≦ k ≦ 30. In particular, the radioisotope of iodine is selected from the radioisotope group of iodine consisting of ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I, more preferably ¹²³ I, ¹²⁴ I, ¹²⁵ I , ¹³¹ I.

More specifically, the present invention relates to a radiolabeled compound of formula (3) or (4).

Formula 3

Formula 3 is one of the compounds of Formula 1, wherein X is a radioisotope of iodine. Specifically, X is selected from the group of radioactive isotopes of iodine consisting of ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I, more preferably ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I .

Formula 4

Formula 4 is one of the compounds of Formula 2, wherein X is a radioisotope of iodine. Specifically, X is selected from the group of radioactive isotopes of iodine consisting of ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I, more preferably ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I .

The compound of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4, which is labeled by a radioisotope, specifically a radioisotope of iodine, binds to various substances such as cells, liposomes, micelles, exosomes, and the like. And a marker which can be used for medical radiography such as positron emission tomography (PET) and photon emission computed tomography (SPECT).

The compound of the present invention has a property of penetrating into living cells can reflect the distribution of cells. In addition, the compound of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4 of the present invention is easy to synthesize, has high cell penetration rate and intracellular accumulation ability. First of all, there is an advantage of enabling the observation of the transition for a sufficient time and the continuous or intermittent imaging for a long time after administration in vivo.

One embodiment to which the compound of the present invention is applied is to use for labeling cells. Labeling of cells consists of a simple process of reacting cells and compounds at room temperature. This allows imaging of the location and distribution of cells introduced into animals, including humans, for the purpose of analysis or treatment, thus providing information on normal and / or abnormalities at the cellular level, progress and migration and trends over time. Results and the like can be effectively obtained for a long time. That is, since it enables the target imaging of the cells to be injected, for example, it is easy to track the expression of the cells, the migration route in the cell therapy, such as administering stem cells.

However, the compounds of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4 of the present invention are not limited to the above-described cell markers, but may be used in vivo cells, liposomes, It can be used as a marker of various substances such as micelles, exosomes and the like.

The present invention encompasses forms wherein the compound is modified or modified to include additional features and functions in the compound of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4. For example, when the target factor is directly or indirectly linked to the compound through a linker or the like, the compound can be used as a marker for target-oriented diagnosis and treatment for various diseases including tumors. In addition, an existing therapeutic agent such as an immunotherapeutic agent, cytokine, chemokine, toxin or the like can be directly bound to the compound of the present invention directly or indirectly through a linker.

The present invention also relates to a composition comprising the radiolabeled compound of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4.

The composition of the present invention may comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, but are not limited to, any solvents, dispersion media, coatings, isotonic agents, dose enhancers, absorption delaying agents, and the like. In addition, further active ingredients may be incorporated into the compositions. The pH and exact concentration can be adjusted according to well known factors. In addition, it may further include a predetermined material required for imaging of the radiographic imaging technique.

The compositions of the present invention can be administered via the general route of use in the water, medical field, for example via the intravenous, intraperitoneal, intramuscular, subcutaneous or topical route.

Specific application examples of the composition are as follows.

Labeling the cells by reacting the cells administered into the subject with a composition of the invention; Administering the labeled cells into the subject; And analyzing the distribution and migration of cells administered in or in some tissues of the individual through radiographic techniques. Analytical radiographic imaging techniques include, but are not limited to, positron emission tomography, photon emission computed tomography, gamma camera imaging, and the like.

An individual to which the compound of formula (I) or formula (2), more preferably the compound of formula (3) or formula (4) or a composition comprising the compound of the present invention may be administered, is a mammal, including a human. Livestock such as, for example, cattle, sheep, goats, cows, swine, etc .; Poultry such as chickens, ducks, geese, turkeys and the like; Pets such as dogs, cats, and the like; It can be administered into a subject of an experimental animal such as a rodent (eg mouse, rat, hamster), rabbit, and the like.

The present invention also relates to a method for preparing a radiolabeled compound of formula (1) or (2), more preferably formula (3) or (4).

Compound of Formula 1, more preferably Formula 3, synthesizes oleyl-4-tributyltinbenzoate from oleyl-4-iodobenzoate (OIB) And labeling it with radioactive iodine.

Compound of formula (2), more preferably formula (4) synthesizes hexadecyl-4-tributylstannylbenzoate from hexadecyl-4-iodobenzoate (HIB) and It can be prepared by a process of labeling it with radioactive iodine.

As a specific example of preparing the compound of Formula 1, more preferably, Formula 3, oleyl alcohol, 4-iodobenzoyl chloride, methylene chloride and triethylamine are reacted to oleyl-4-iodobenzoate of Formula 5 To obtain; Reacting the oleyl-4-iodobenzoate with hexabutylditin and tetrakis (triphenylphosphine) palladium to obtain a compound of formula 6; And reacting the compound of Formula 6 with a radioactive iodine metal salt to obtain a compound of Formula 1, more preferably Formula 3.

Formula 5

Formula 6

In the above formula, R is not particularly limited, but is preferably a linear or branched alkyl group or aromatic substituent, more preferably a linear or branched alkyl group having 1 to 6 carbon atoms or aromatic substituent.

As a specific example of preparing the compound of Formula 2, more preferably Formula 4, hexadecyl-4-iodo of Formula 7 is reacted with 1-hexadecanol, 4-iodobenzoyl chloride, methylene chloride and triethylamine Obtaining benzoate; Reacting the hexadecyl-4-iodobenzoate with hexabutylditin and tetrakis (triphenylphosphine) palladium to obtain a compound of formula 8; And reacting the compound of Formula 8 with a radioactive iodine metal salt to obtain a compound of Formula 2, more preferably Formula 4.

Formula 7

Formula 8

Specifically in the process for preparing the compound of Formula 1 or Formula 2, more preferably Formula 3 or Formula 4, the radioactive iodine is radioactive of iodine consisting of ¹²² I, ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I and ¹³² I Isotope group, more preferably ¹²³ I, ¹²⁴ I, ¹²⁵ I, ¹³¹ I. In addition, the radioactive iodine isotopes are provided in the form of metal iodide salts, and any one capable of providing radioactive ions is possible, but alkali metal salts such as sodium iodide, potassium iodide and lithium iodide are preferred.

The reagents, solvents and reactions required for each of these processes are well known to those skilled in the art of synthesis. In addition, in the production process, the intermediate reaction product can be separated from the reaction medium and further purified according to methods generally known in the art, such as extraction, crystallization and chromatography, if necessary. Starting materials, intermediates and the like used in the reaction process can be obtained commercially or prepared according to methods known in the art.

However, the method for synthesizing the compound of the present invention is not limited to the above. The preparation of each process can be diversified and can be carried out by applying various methods well known in the art for synthesis.

The present invention also relates to a compound represented by the following formula (6) or (8).

In Formula 6 or Formula 8, R is not particularly limited, but is preferably a linear or branched alkyl group or aromatic substituent, more preferably a linear or branched alkyl group having 1 to 6 carbon atoms or aromatic substituent. have.

In the present invention, Chemical Formula 6 is a precursor of the radiolabeled compound represented by Chemical Formula 1, preferably Chemical Formula 3, and the compound of Chemical Formula 8 is a precursor of the radiolabeled compound represented by Chemical Formula 2, preferably Chemical Formula 4 of the present invention. .

In addition, the present invention relates to cells, liposomes, exosomes or micelles labeled with a radiolabeled compound represented by any one of Formulas 1 to 4. Cells, liposomes, exosomes or micelles labeled with the radiolabeled compound of the present invention can be traced for a long time when applied to nuclear medical imaging. The nuclear medicine imaging method is a method of capturing cancer or examining organ function by capturing radiation emitted from the radioisotope by administering a drug containing a radioisotope in the human body.

The radioactive cell labeling compounds of the present invention are simple to synthesize and are labeled on cells with high efficiency. In addition, the compounds of the present invention were able to track up to about 2 weeks in a non-invasive way. Therefore, when using the compound of the present invention, cells labeled with the compound of the present invention can be traced to cells for a long time through nuclear medicine imaging.

1 shows the ¹ H NMR results of OIB.

2 shows ¹³ C NMR results of OIB.

3 shows the ¹ H NMR results of the [ ¹³¹ I] OIB precursor.

4 shows ¹³ C NMR results of the [ ¹³¹ I] OIB precursor.

5 shows the ¹ H NMR results of HIB.

6 shows the ¹³ C NMR results of HIB.

Figure 7 shows the ¹ H NMR results of the [ ¹³¹ I] HIB precursor.

8 shows ¹³ C NMR results of the [ ¹³¹ I] HIB precursor.

9 shows Radio TLC results after the reaction of [ ¹³¹ I] OIB.

10 shows Radio TLC results after purification of [ ¹³¹ I] OIB.

11 shows the yield of [ ¹³¹ I] OIB and [ ¹³¹ I] HIB cell labels.

12 shows a gamma camera image after injecting [ ¹³¹ I] OIB into a rat.

FIG. 13 shows gamma camera and GFP image results after [ ¹³¹ I] OIB is injected into a nude mouse. FIG.

FIG. 14 shows gamma camera imaging results after 30 minutes of injecting [ ¹³¹ I] HIB labeled MDCK cells into mice.

15 shows the results of MicroPET images obtained after injecting [ ¹²⁴ I] HIB into mice using the tail vein.

16 shows the results of MicroPET images obtained after injecting mice labeled with [ ¹²⁴ I] HIB into mice through the tail vein.

17 shows radioactive TLC results for [ ¹³¹ I] HIB produced by another embodiment of the present invention.

18 shows radio-HPLC results for [ ¹³¹ I] HIB produced by another embodiment of the present invention.

19 shows the radiochemical purity of [ ¹³¹ I] HIB produced by another embodiment of the present invention.

20 shows radioactive TLC results for [ ¹²⁴ I] HIB produced by another embodiment of the present invention.

21 shows radio-HPLC results for [ ¹²⁴ I] HIB produced by another embodiment of the present invention.

Figure 22 shows the radiochemical purity of [ ¹²⁴ I] HIB produced by another embodiment of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

Example 1 Synthesis of Oleyl-4-iodobenzoate

Oleyl alcohol (2.7 mL, 9.31 mmol) and triethylamine (2.25) in a mixture of methylene chloride (130 mL) and 4-iodobenzoyl chloride (4-iodobenzoyl chloride) (2.65 g, 9.94 mmol) mL) was added. After the solution was reacted overnight at room temperature, methylene chloride was removed under reduced pressure, and the remaining material was purified by column chromatography (2.80 g, 60%). ¹ H NMR (CDCl ₃ , 400 MHz) 7.78 (4H, ABq, J = 8.48 Hz), 5.36 (2H, m), 4.32 (2H, t, J = 8 Hz), 2.04 (4H, m), 1.77 (2H, m), 1.28-1.44 (22H, m), 0.88 (3H, m). ¹³ CNMR 14.55, 23.11, 26.41, 27.58, 27.63, 29.06, 29.61, 29.66, 29.74, 29.82, 29.95, 30.07, 30.13, 30.18, 32.32, 33.03, 65.76, 100.97, 130.14, 130.60, 130.84, 138.32, 166.46

Example 2 Synthesis of Oleyl-4-tributyltinbenzoate

Hexabutylditin (1ml, 1.39mmol) and tetrakis (triphenylphosphine) in a solution containing oleyl-4-iodobenzoate (0.46g, 0.87mmol) in 150ml of toluene palladium) (0.02 g, 17.3 μmol) was added and refluxed under argon until the color of the mixture became black. The solvent was removed under reduced pressure, and the remaining material was purified by column chromatography (0.37 g, 61%). ¹ H NMR (CDCl ₃ , 400 MHz) 7.99 (2H, d, J = 8 Hz), 7.62 (2H, d, J = 8 Hz), 5.39 (2H, m), 4.33 (2H, t, J = 8 Hz), 2.05 (4H, m), 1.8 (2H, m), 1.12-1.57 (22H, m), 0.91 (12H, m). ¹³ CNMR (CDCl ₃ , 400 MHz) 10.03,14.06, 14.52, 23.10, 26.46, 27.59, 27.62, 27.73, 29.44, 29.69, 30.14, 30.18, 32.30, 33.02, 65.36, 128.55, 130.65, 130.83, 136.76, 149.79, 166.48.

Example 3 Synthesis of [ ¹³¹ I] OIB

^[131 I] was reacted OIB precursor (50μl, 1mg / 1ml) in HCl 1M (50μl), 3% H ₂ O ₂ (50μL) and ^[131 I] for 20 min at room temperature after inserting the NaI (2.25mCi). Sat on the reaction. NaHSO ₃ (50 μl) was added and quenched. The product was purified by HPLC (Luna C8 column, 5 μm, 4.6 × 50 mm, mobile phase 95% acetonitrile in dH ₂ O, flow rate 1 ml / min). The solvent was removed under reduced pressure, and the separated [ ¹³¹ I] OIB was dissolved in 10% DMSO / saline. Activity obtained by the above method was 817 μCi (36%, radiochemical yield, synthesis time 2 hrs).

Example 4 [ ¹³¹ I] L6 Cell Labeling Using OIB

33 μl (136 μCi) of [ ¹³¹ I] OIB in 10% DMSO / saline was added to 4 × 10 ⁵ L6 cells in 0.5 ml serum-free medium. The mixture was reacted at room temperature for 30 minutes. Cells were washed twice with PBS (phosphate-buffered saline, pH 7.4) after removing the support by using a centrifuge (2000xg for 2min). Combined radioactivity of the isolated cells and media after washing was measured by dose calibrator (Capintec radioisotope calibrator). Cell labeling efficiency was 26%. The loss of labeled cells was determined by the loss of radioactivity during cell centrifugation or washing with PBS.

Example 5 Gamma Camera and GFP Image

Mice were placed on the head of a Triad XLT gamma camera (Tronix, Twinsburg, OH) and injected with L6 cells labeled with [ ¹³¹ I] OIB. The head of the camera was equipped with MEGP (medium energy general purpose v collimator) equipment. Images were measured for the first 5 minutes with a 256x256 matrix. The film was then acquired for one, two, and two weeks.

Example 6 Synthesis of Hexadecyl-4-iodobenzoate

1-hexadecanol (1 g, 4.12 mmol), 4-iodobenzoyl chloride (1.32 g, 4.94 mmol), triethyl-amine (1.15 ml, 8.25 mmol) and methylene chloride (30 ml) were reacted at room temperature for 3 hours. The solvent was removed under reduced pressure, and white residue was obtained using hexane from the residue (1.42 g, 80%).

Example 7 Synthesis of Hexadecyl-4-tributyl stannyl benzoate

Hexabutylditin (0.78ml, 1.56mmol) and tetrakis (triphenylphosphine) palladium (0.02g, 19.4μmol) in hexadecyl-4 in 10ml toluene It was added to iodobenzoate (hexadecyl-4-iodobenzoate) (0.46 g, 0.9 mmol). The mixture was refluxed until the solution was black (6-8 hours). The solvent was removed under reduced pressure and the residue was obtained by column chromatography (alumina) (hexanes / ethyl acetate = 20/1 (v / v)) to give a colorless product (0.43 g, 70%).

Example 8 Synthesis of [ ¹³¹ I] HIB

1 M HCl (50 μl), 3% H ₂ O ₂ (50 μL) and [ ¹³¹ I] NaI (2.75 mCi) were added to [ ¹³¹ I] HIB precursor (50 μl, 1 mg / 1 ml) and reacted at room temperature for 20 minutes. The reaction was sat. NaHSO ₃ (50 μl) was added and quenched. The product was purified by HPLC (Luna C8 column, 5 μm, 4.6 × 50 mm, mobile phase 95% acetonitrile in dH ₂ O, flow rate 1 ml / min). The solvent was removed under reduced pressure, and the separated [ ¹³¹ I] OIB was dissolved in 10% DMSO / saline. The activity obtained by this method was 1.815 mCi (66%, radiochemical yield, synthesis time 2 hrs).

Example 9 Synthesis of [ ¹²⁴ I] HIB

Add 30% H ₂ O ₂ / AcOH (100 μL, 1/3 v / v) and [ ¹²⁴ I] NaI (0.3 mCi) to [ ¹²⁴ I] HIB (50 μl, 1 mg / 1 ml) precursor for 10 minutes at room temperature Reacted. The reaction was quenched by adding 0.1N HCl (100 μl) to the reaction. The product was purified by HPLC (Luna C8 column, 5 μm, 4.6 × 50 mm, mobile phase 95% acetonitrile in dH ₂ O, flow rate 1 ml / min). The solvent was removed under reduced pressure and the separated [ ¹²⁴ I] HIB was dissolved in 10% DMSO / saline. The activity obtained by the above method was 75 μCi (25%, radiochemical yield, synthesis time 2 hrs).

Example 10 Synthesis of [ ¹³¹ I] oIB (oleyliodobenzoate) and [ ¹³¹ I] HIB (hexadecyl iodobenzoate) precursor

After adding 4-iodobenzoyl chloride to a mixture of triethylamine and oleyl alcohol dissolved in methylene chloride, the mixture was reacted at room temperature overnight, and then column chromatography was performed to obtain OIB (oleyl-4-iodobenzoate) ester (1) 56% Got it. The synthesis process of [ ¹³¹ I] OIB precursor is shown in Scheme 1. The produced compound could be confirmed by ¹ H NMR and ¹³ C NMR (FIGS. 1 and 2).

Scheme 1

The ester compound (1) was reacted with a hexabutyltin compound under a palladium catalyst to obtain a [ ¹³¹ I] OIB precursor (2) in which the iodine group was substituted with a tributyltin group in 61% yield. Synthesized Compound (2) was confirmed by ¹ H NMR and ¹³ C NMR (Fig. 3 and 4).

4-iodobenzoyl chloride was added to a mixture of triethylamine and hexadecylalcohol dissolved in methylene chloride, and then reacted at room temperature overnight, followed by hexadecyl-4 through column chromatography. -80% of the ester which is iodobenzoate (HIB) was obtained. Synthesis of the [ ¹³¹ I] HIB precursor is shown in Scheme 2. The produced compound was confirmed by ¹ H NMR and ¹³ C NMR. The ester compound was reacted with a hexabutyltin compound under a palladium catalyst to give [ ¹³¹ I] HIB precursor in which the iodine group was substituted with the tributyltin group in 70% yield. The synthesized compound was confirmed by ¹ H NMR and ¹³ C NMR (Figs. 5, 6, 7 and 8).

Scheme 2

Example 11 Synthesis Results of [ ¹³¹ I] OIB, [ ¹³¹ I] HIB and [ ¹²⁴ I] HIB

The [ ¹³¹ I] OIB precursor was reacted with I-131 and 3% hydrogen peroxide under 1 M hydrochloric acid to obtain [ ¹³¹ I] OIB in 51% yield. Synthesis of [ ¹³¹ I] OIB is shown in Scheme 3. Yield was calculated based on radio-TLC as incorporation yield (FIGS. 9 and 10). Synthesized [ ¹³¹ I] OIB was purified by HPLC, the purity was more than 95%.

Scheme 3

[ ¹³¹ I] HIB was synthesized in 66% yield in the same manner as in the synthesis of [ ¹³¹ I] OIB. Synthesis of [ ¹³¹ I] HIB is shown in Scheme 4.

Scheme 4

The [ ¹²⁴ I] HIB precursor was reacted with I-124 and 30% hydrogen peroxide to obtain [ ¹²⁴ I] HIB in 25% yield. Synthesis of [ ¹²⁴ I] HIB is shown in Scheme 5. Yield was calculated based on radio-TLC as incorporation yield. [ ¹²⁴ I] HIB synthesized was purified by HPLC and the purity was over 99%.

Scheme 5

Example 12 Cell Labeling Results of [ ¹³¹ I] OIB and [ ¹³¹ I] HIB

Cell labeling was performed by putting [ ¹³¹ I] OIB and [ ¹³¹ I] HIB, and cells into PBS solution, mixing the cells, and separating the cells using a centrifuge, followed by washing several times. Cell labeling proceeded for L6, H9C2, HeLa, 4T1 and SCC-7 (FIG. 11). The cell label yield is 20% or more for all five kinds of cells.

Example 13 Gamma Camera Image Result

After using the cell marker [ ¹³¹ I] OIB for 2 hours in rat cardiomyocyte L6, labeled cardiomyocytes were directly transplanted into the myocardium of rats, and images were obtained by gamma camera for 2 weeks. Images were taken of cells transplanted via [ ¹³¹ I] OIB and no metastasis of other organs was seen for 2 weeks (FIG. 12). Cells to which the L6-NIS / GFP reporter had been introduced were labeled with the [ ¹³¹ I] OIB compound, and then subcutaneously injected into the thighs and shoulders of nude mice at a number of 1 × 10 7 cells. From day 1 to day 14 after injection, images of [ ¹³¹ I] OIB-labeled cells were imaged with gamma cameras. Then, 24 days after injection of 500 μCi Tc-99m into the abdominal cavity, images were obtained by gamma cameras. . GFP gene was measured up to 24 days. [ ¹³¹ I] OIB could be seen up to 14 days in gamma camera images, and GFP images could be measured up to 14 days (Fig. 13). In addition, MDCK vertically labeled [ ¹³¹ I] HIB was accumulated in the lungs when viewed with a gamma camera 30 minutes after injection into the mouse (FIG. 14).

Example 14 MicroPET Image

[ ¹²⁴ I] HIB was injected into mice using tail vein and microPET images were obtained. At this time, it was confirmed that [ ¹²⁴ I] HIB was accumulated in the thyroid gland and the bladder, which is the site of iodine. In addition, the activity accumulates in the liver position, which is believed to be excreted through the liver (FIG. 15).

After injecting labeled cells using [ ¹²⁴ I] HIB through the tail vein, microPET images were obtained. At this time, it was confirmed that most of them accumulated in the lungs, which is thought to be due to the fact that most of the cells are trapped in the capillaries of the lungs. Continuous imaging of the same animal over time confirmed the possibility of long-term observation. MicroPET imaging was obtained for 2 hours after the cells were injected, and the images were confirmed to have accumulated in the lung area for 2 hours after the injection and 2 hours after the injection and 66 hours (about 3 days) (FIG. 16). . Therefore, it was confirmed that [ ¹²⁴ I] HIB can be used as a cell trafficking agent for a long time.

Example 15 Another Synthesis Method of [ ¹³¹ I] HIB

Another synthesis of [ ¹³¹ I] HIB is as follows. In hexadecyl-4-tributyl stannyl benzoate (100 μg) obtained in Example 7, acetic acid (100 μL), 3% H ₂ O ₂ (100 μL), 0.1 N HCl (100 μL) and NaI ¹³¹ (1.73 mCi) solution were mixed and reacted at 70 ° C. for 30 minutes to obtain product [ ¹³¹ I] HIB. Another synthetic process of [ ¹³¹ I] HIB is shown in Scheme 6 below.

Scheme 6

The product [ ¹³¹ I] HIB was identified by radio-TLC (radio-TLC) using a mobile phase 20: 1 Hexane: EtOAC in a silica plate. After removing the solvent in a 50 ° C. vacuum, the isolated [ ¹³¹ I] HIB was dissolved in 20% DMSO / PBS. Activity obtained by the above method was 1.56 mCi (> 90% radiochemical yield, no attenuation correction, synthesis time 40 min) (FIG. 17).

In addition, radio-HPLC analysis for the product [ ¹³¹ I] HIB [Luna C8 column, 4.6 X 50 mm, 5 μιη, isocratic method (MeCN: H ₂ 0 = 95: 5, flowrate = 1 mL /) min)] and the results are shown in FIG. As a result of the measurement of radio-TLC and radio-HPLC, the radiochemical purity of the product [ ¹³¹ I] HIB was 99% or more (FIG. 19).

Example 16 Another Synthesis Method of [ ¹²⁴ I] HIB

Another synthesis of [ ¹²⁴ I] HIB is as follows. In hexadecyl-4-tributyl stannyl benzoate (100 μg) obtained in Example 7, acetic acid (100 μL), 3% H ₂ O ₂ (100 μL), 0.1 N HCl (100 μL) and NaI ¹²⁴ (1.56 mCi) solution were mixed and reacted at 70 ° C. for 30 minutes to obtain product [ ¹²⁴ I] HIB. Another synthetic process of [ ¹²⁴ I] HIB is shown in Scheme 7 below.

Scheme 7

The product [ ¹²⁴ I] HIB was identified by radioactive TLC using mobile phase 20: 1 Hexane: EtOAC in a silica plate. After removal of solvent in 50 ° C. vacuum, the isolated [ ¹²⁴ I] HIB was dissolved in 20% DMSO / PBS. Activity obtained by the above method was 1.42 mCi (98% radiochemical yield, no attenuation correction, synthesis time 40 min) (FIG. 20).

Radio-HPLC analysis for the product [ ¹²⁴ I] HIB [Luna C8 column, 4.6 X 50 mm, 5 μιη, isocratic method (MeCN: H ₂ O = 95: 5, flowrate = 1 mL / min) ], And the result is as shown in FIG. As measured by radio-TLC and radio-HPLC, radiochemical purity was greater than 99% (FIG. 22).

Compounds of the present invention that can be traced by imaging the position and distribution of cells flowing in vivo for a long time, applications in basic research fields such as biomedical sciences and genetic fields, and clinical fields for cell therapy and regeneration This is expected.

Claims

A radiolabeled compound represented by the following formula (1).

<Formula 1>

Wherein X is a radioisotope of iodine and 5 ≦ i + j ≦ 30. N of the double bond (—CH═CH—) moiety is 1 to 10 and the double bond is continuous or discontinuous Combined)
A radiolabeled compound represented by the following formula (2).

<Formula 2>

(Wherein X is a radioisotope of iodine and 5 ≦ k ≦ 30).
The method of claim 1,

A radiolabeled compound characterized by the following formula (3).

<Formula 3>

Wherein X is the radioisotope of iodine.
The method of claim 2,

A radiolabeled compound characterized by the following formula (4).

<Formula 4>

Wherein X is the radioisotope of iodine.
The method according to any one of claims 1 to 4,

X is a radiolabeled compound, characterized in that selected from the group of radioactive isotopes of iodine consisting of 122 I, 123 I, 124 I, 125 I, 131 I and 132 I.
A composition comprising a radiolabeled compound of Formula 1, Formula 2.

<Formula 1>

(Wherein X is a radioisotope of iodine, 5 ≦ i + j ≦ 30, and N is 1-10).

<Formula 2>

(Wherein X is a radioisotope of iodine and 5 ≦ k ≦ 30).
7. The composition of claim 6, wherein X is selected from the group of radioactive isotopes of iodine consisting of 122 I, 123 I, 124 I, 125 I, 131 I and 132 I.
Reacting oleyl alcohol, 4-iodobenzoyl chloride, methylene chloride and triethylamine to obtain oleyl-4-iodobenzoate of formula 5;

Reacting the oleyl-4-iodobenzoate with hexabutylditin and tetrakis (triphenylphosphine) palladium to obtain a compound of formula 6; And

A method for preparing the radiolabeled compound of claim 1, comprising the step of reacting the compound of formula 6 with a radioactive iodine metal salt to obtain a compound of formula 1.

<Formula 5>

<Formula 6>

(Wherein R is a linear or branched alkyl or aromatic substituent)
Reacting 1-hexadecanol, 4-iodobenzoyl chloride, methylene chloride and triethylamine to obtain hexadecyl-4-iodobenzoate of formula (7);

Reacting the hexadecyl-4-iodobenzoate with hexabutylditin and tetrakis (triphenylphosphine) palladium to obtain a compound of formula 8; And

A method for preparing the radiolabeled compound of claim 2, comprising the step of reacting the compound of formula 8 with a radioactive iodine metal salt to obtain a compound of formula 2.

<Formula 7>

<Formula 8>

(Wherein R is a linear or branched alkyl or aromatic substituent)
10. The method of claim 8 or 9, wherein the iodine is selected from the radioisotope group of iodine consisting of 122 I, 123 I, 124 I, 125 I, 131 I and 132 I.
A compound represented by the following formula (6).

<Formula 6>

(Wherein R is a linear or branched alkyl or aromatic substituent)
A compound represented by the following formula (8).

<Formula 8>

(Wherein R is a linear or branched alkyl or aromatic substituent)
A cell labeled with the radiolabelled compound of any one of claims 1 to 5.
Liposomes labeled with the radiolabelled compound of any one of claims 1 to 5.
Exosomes labeled with the radiolabelled compound of any one of claims 1 to 5.
Micelles labeled with the radiolabelled compound of any one of claims 1 to 5.